Company overview
Cencora provides comprehensive wholesale and specialty distribution of pharmaceuticals, including brand/generic drugs, hospital supplies, and biosimilars, through secure global supply chains. They offer third-party logistics (3PL) via Alloga and ICS, temperature-controlled warehousing, and customs expertise for worldwide delivery. Additional services include supply chain consulting, shortage mitigation programs like Sure Supply, and strategies for regulatory compliance and efficiency.
Cencora is listed in the NovaPharmaNews Supplier Hub as a Cold Chain & Packaging partner serving United States & Americas. Core focus areas include cencora, pharma distribution, supply chain, 3pl logistics, specialty pharma.
Industry categories: Cold Chain & Packaging. These tags help R&D, manufacturing, and procurement teams discover vendors aligned with their pipeline stage and compliance requirements.
Structured facts
- Website
- https://www.cencora.com/
- Categories
- Cold Chain & Packaging
- Markets served
- United States & Americas
- Keywords
- cencora, pharma distribution, supply chain, 3pl logistics, specialty pharma
Products & technologies
Markets served
Industry categories
Company timeline
- — Profile published on NovaPharmaNews
- — Profile last updated
Related suppliers in category
Frequently asked questions
- What distribution capabilities does Cencora offer for pharmaceuticals?
- Cencora provides wholesale and specialty distribution networks for brand/generic drugs, consumer products, hospital supplies, and biosimilars, with innovative solutions for secure global supply chains.
- What are Cencora's regulatory and compliance features?
- Cencora ensures compliance through specialized packaging, customs expertise, temperature-controlled warehousing, and consulting to handle regulatory changes, shortages, and global requirements.
- In which geographies does Cencora operate?
- Cencora leverages a global network for logistics, warehousing, and distribution, supporting therapy launches in new markets and shipments across continents with local expertise.
Related editorial coverage
- Aurobindo Pharma OAI Classification: Implications for Drug Approvals
- Cencora-Kite Agreement: A New Era for CAR T-cell Therapy Commercialization
- DCAT Week 2024: Strategic Imperatives for Pharma BD and Investors
- ASGCT: Key Manufacturing Innovations Day 1
- IPEC Annual Meeting: Key Highlights and Industry Insights
- FDLI Annual 2026: Key Regulatory Updates and Industry Trends
Explore lab tools and QA/QC resources for R&D teams.
